Set - Out - Português

acroglobulinemia

aldenström

–

uma

revisão

ssoc

ras

2014; 60(5):490-499

499

27.

Rajkumar SV. Epidemiology, pathogenesis, clinical manifestations and

diagnosis of Waldenströmmacroglobulinemia. In: Schrier S, Kyle R, Connor

R (eds.). UpToDate. Waltham: UpToDate, 2012.

28.

Ropper AH, Gorson KC. Neuropathies associated with paraproteinemia. N

Engl J Med 1998; 338:1601-7.

29. Whittaker SJ, Bhogal BS, Black MM. Acquired immunobullous disease: a

cutaneous manifestation of IgMmacroglobulinaemia. Br J Dermatol 1996;

135:283-6.

30. Daoud MS, Lust JA, Kyle RA, PittelkowMR. Monoclonal gammopathies and

associated skin disorders. J Am Acad Dermatol 1999; 40:507-35.

31. Riviere E, Ghiringhelli CB, Peyrot I, Lippa N, Laffitte A, Roger-Schmeltz J et

al. Macroglobulinosis cutis revealing Waldenströmmacroglobulinemia. Rev

Med Interne 2011; 32:18-20.

32. Kastritis E, Katoulis A, Terpos E, Panayiotides I, Gavriatopoulopu M,

Dimopopoulos M. Schnitzler’s syndrome: increased levels of bone formation

and angiogenesis factors are reduced after successful pefloxacin treatment.

Clin Lymphoma 2008; 8:359-62.

33. Gad A, Willen R, Carlen B, Gyland F, Wickander M. Duodenal involvement

in Waldenström’s macroglobulinemia. J Clin Gastroenterol 1995; 20:174-6.

34.

Morel-Maroger L, Basch A, Danon F, Verroust P, Richet G. Pathology of the

kidney in Waldenström’s macroglobulinemia. Study of sixteen cases. N Engl

J Med 1970; 283:123-9.

35. Gertz M, Kyle R, Noel P. Primary systemic amyloidosis: a rare complication

of immunoglobulin M monoclonal gammopathies and Waldenström’s

macroglobulinemia. J Clin Oncol 1993; 11:914-20.

36. Gertz MA, Kyle RA. Amyloidosis with IgMmonoclonal gammopathies. Semin

Oncol 2003; 30:325-8.

37.

Moyner K, Sletten K, Husby G, Natvig JB. An unusually large (83 amino acid

residues) amyloid fibril protein AA from a patient with Waldenström’s

macroglobulinaemia and amyloidosis. Scand J Immunol 1980; 11:549-54.

38.

Shah IA, Netto D, Ashfaq R, Krieger C. Waldenström’s macroglobulinemia

associated with generalized AA-amyloidosis. Int J Surg Pathol 1993; 1:123-7.

39. Gardyn J, Schwartz A, Gal R, Lewinski U, Kristt D, Am C. Waldenström’s

macroglobulinemia associated with AA amyloidosis. Int J Hematol 2001;

74:76-8.

40. Hunter ZR, Manning RJ, Hanzis C, Ciccarelli BT, Ioakimidis L, Patterson CJ

et al. IgA and IgG hypogammaglobulinemia in Waldenström’s

macroglobulinemia. Haematologica 2010; 95:470-5.

41.

Singh A, Eckardt KU, Zimmermann A, Götz KH, Hamann M, Ratcliffe PJ et

al. Increased plasma viscosity as a reason for inappropriate erythropoietin

formation. J Clin Invest 1993; 91:251-6.

42. Roux S, Fermand JP, Brechignac S, Mariette X, Kahn MF, Brouet JC. Tumoral

joint involvement inmultiple myeloma andWaldenström’s macroglobulinemia

– report of 4 cases. J Rheumatol 1996; 23:2175-8.

43. Kaila VL, El-Newihi HM, Dreiling BJ, Lynch CA, Mihas AA. Waldenström’s

macroglobulinemia of the stomach presenting with upper gastrointestinal

hemorrhage. Gastrointest Endosc 1996; 44:73-5.

44. Yasui O, Tukamoto F, Sasaki N, Saito T, Yagisawa H, Uno A et al. Malignant

lymphoma of the transverse colon associated with macroglobulinemia. Am

J Gastroenterol 1997; 92:2299-301.

45. Rosenthal JA, Curran WJ, Schuster SJ. Waldenström’s macroglobulinemia

resulting from localized gastric lymphoplasmacytoid lymphoma. Am J Hematol

1998; 58:244-5.

46. Recine MA, Perez MT, Cabello-Inchausti B, Lilenbaum RC, Robinson MJ.

Extranodal lymphoplasmacytoid lymphoma (immunocytoma) presenting as

small intestinal obstruction. Arch Pathol Lab Med 2001; 125:677-9.

47. Rausch PG, Herion JC. Pulmonary manifestations of Waldenström

macroglobulinemia. Am J Hematol 1980; 9:201-9.

48. Fadil A, Taylor DE. The lung and Waldenström’s macroglobulinemia. South

Med J 1998; 91:681-5.

49. Veltman GA, van Veen S, Kluin-Nelemans JC, Bruijn JA, van Es LA. Renal

disease in Waldenström’s macroglobulinaemia. Nephrol Dial Transplant

1997; 12:1256-9.

50.

Mascaro JM, Montserrat E, Estrach T, Feliu E, Ferrando J, Castel T et al. Specific

cutaneous manifestations of Waldenström’s macroglobulinaemia. A report

of two cases. Br J Dermatol 1982; 106:17-22.

51. Orellana J, Friedman AH. Ocular manifestations of multiple myeloma,

Waldenström’s macroglobulinemia and benign monoclonal gammopathy.

Surv Ophthalmol 1981; 26:157-69.

52. Ettl AR, Birbamer GG, Philipp W. Orbital involvement in Waldenström’s

macroglobulinemia: ultrasound, computed tomography and magnetic

resonance findings. Ophthalmologica 1992; 205:40-5.

53. Civit T, Coulbois S, Baylac F, Taillandier L, Auque J. Waldenström’s

macroglobulinemia and cerebral lymphoplasmocytic proliferation: Bing and

Neel syndrome. Apropos of a new case. Neurochirurgie 1997; 43:245-9.

54. Lin P, Mansoor A, Bueso-Ramos C, Hao S, Lai R, Medeiros LJ. Diffuse large

B-cell lymphoma occurring in patients with lymphoplasmacytic lymphoma/

Waldenström macroglobulinemia - clinicopathologic features of 12 Cases.

Am J Clin Pathol 2003; 120:246-53.

55. Feiner HD, Rizk CC, Finfer MD, Bannan M, Gottesman SR, Chuba JV et al.

IgM monoclonal gammopathy/Waldenström’s macroglobulinemia: a

morphological and immunophenotypic study of the bone marrow. Mod

Pathol 1990; 3:348-56.

56.

San Miguel JF, Vidriales MB, Ocio E, Mateo G, Sánchez-Guijo F, Sánchez ML

et al. Immunophenotypic analysis of Waldenström’s macroglobulinemia.

Semin Oncol 2003; 30:187-95.

57. Pangalis G, Kyrtsonis M-C, Kontopidou F, Siakantaris M, Dimopoulou M,

VassilakopoulosTetal.DifferentialdiagnosisofWaldenström’smacroglobulinemia

and other B-Cell disorders. Clin Lymphoma 2005; 5:235-40.

58. Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF et al.

A long-term study of prognosis in monoclonal gammopathy of undetermined

significance. N Engl J Med 2002; 346:564-9.

59. Kyle RA, Therneau TM, Rajkumar SV, Remstein ED, Offord JR, Larson DR

et al. Long-term follow-up of IgMmonoclonal gammopathy of undetermined

significance. Blood. 2003; 102:3759-64.

60. Fonseca R, Hayman S. Waldenström macroglobulinaemia. Br J Haematol

2007; 138:700-20.

61.

Morel P, Duhamel A, Gobbi P, Dimopoulos MA, Dhodapkar MV, McCoy J et

al. International prognostic scoring system for Waldenström

macroglobulinemia. Blood 2009; 113:4163-70.

62. Kastritis E, Kyrtsonis MC, Hadjiharissi E, Symeonidis A, Michalis E, Repoussis

P et al. Validation of the International Prognostic Scoring System (IPSS) for

Waldenström’s macroglobulinemia (WM) and the importance of serum lactate

dehydrogenase (LDH). Leuk Res 2010; 34:1340-3.

63. TreonSP.HowItreatWaldenströmmacroglobulinemia.Blood2009;114:2375-85.

64. DimopoulosMA, GertzMA, Kastritis E, Garcia-Sanz R, Kimby EK, LeBlond V et

al. Update on treatment recommendations from the Fourth International

Workshop onWaldenström’s macroglobulinemia. J ClinOncol 2009; 27:120-6.

65. VijayA,GertzM.CurrenttreatmentoptionsforWaldenströmmacroglobulinemia.

Clin Lymphoma 2008; 8:219-29.

66. Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, Zervas K, Tsatalas C,

Kokkinis G et al. Primary treatment of Waldenström macroglobulinemia

with dexamethasone, rituximab, and cyclophosphamide. J Clin Oncol 2007;

25:3344-9.

67. Jaglowski SM, Alinari L, Lapalombella R, Muthusamy N, Byrd JC. The clinical

application of monoclonal antibodies in chronic lymphocytic leukemia. Blood

2010; 116:3705-14.

68.

Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of

action and resistance. Oncogene 2003; 22:7359-68.

69. Treon SP, Hansen M, Branagan AR, Verselis S, Emmanouilides C, Kimby E et

al. Polymorphisms in Fc

RIIIA (CD16) receptor expression are associated with

clinical response to rituximab in Waldenström’s macroglobulinemia. J Clin

Oncol 2005; 23:474-81.

70. Ghobrial IM, Fonseca R, Greipp PR, Blood E, Rue M, Vesole DH et al. Initial

immunoglobulinM ‘flare’ after rituximab therapy in patients diagnosed with

Waldenströmmacroglobulinemia. Cancer 2004; 101:2593-8.

71. Dimopoulos MA, Zervas C, Zomas A, Kiamouris C, Viniou NA, Grigoraki V

et al. Treatment of Waldenström’s macroglobulinemia with rituximab. J Clin

Oncol 2002; 20:2327-33.

72. Treon SP, Branagan AR, Hunter Z, Santos D, Tournhilac O, Anderson KC.

Paradoxical increases in serum IgM and viscosity levels following rituximab

in Waldenström’s macroglobulinemia. Ann Oncol 2004; 15:1481-3.

73.

Issa GC, Ghobrial IM, Roccaro AM. Novel agents in Waldenström

macroglobulinemia. Clin Invest (Lond) 2011; 1:815-24.

74. Owen RG, Kyle RA, Stone MJ, Rawstron AC, Leblond V, Merlini G et al.

Response assessment in Waldenström macroglobulinaemia: update from

the VIth International Workshop. Br J Haematol 2013; 160:171-6.

75. Ciccarelli BT, Yang G, Hatjiharissi E, Ioakimidis L, Patterson CJ, Manning

RJ et al. Soluble CD27 is a faithful marker of disease burden and is unaffected

by the rituximab-induced IgM flare, as well as by plasmapheresis, in patients

with Waldenström’s macroglobulinemia. Clin Lymphoma 2009; 9:56-8.

76.

Itzykson R, Le Garff-Tavernier M, Katsahian S, Diemert MC, Musset L,

Leblond V. Serum-free light chain elevation is associated with a shorter time

to treatment in Waldenström’s macroglobulinemia. Haematologica 2008;

93:793-4.